Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan

Contributed by: Business Wire

Logo

Tags

Pharmaceutical

Health

Neurology

Japan

More Like This

Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity

Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine